THE USE OF GENE THERAPY THROUGH BEVACIZUMAB IN THE TREATMENT OF COLORECTAL CANCER AN INTEGRATIVE REVIEW
Article Sidebar
Submitted
January 6, 2022
Published
January 6, 2022
Abstract
Colorectal cancer is a pathology that affects the individual's gastro-intestinal tract, affecting from the large intestine to the anus. The treatment of this cancer consists of surgical procedure, chemotherapy and radiotherapy. Currently, the combination of bevacizumab with traditional chemotherapy for CRC (colorectal cancer) has been used, since bevacizumab is a monoclonal antibody whose mechanism of action is to inhibit the growth of new blood vessels that would carry nutrients to the tumor. Treatment through gene therapy associated with bevacizumab has shown to be very promising in the treatment of colorectal cancer, seeking to reduce recurrences, mortality and toxicities caused by the treatment. The present study aimed to evaluate how the use of bevacizumab associated with gene therapy has shown promise in the treatment of colorectal cancer. For data collection, an integrative literature review was carried out, where through consultations in the databases, PubMed, SciELO (Scientific Electronic Library Online) and VHL(Virtual Health Libraries), articles published in the last 5 years were selected (period from 2016 to December of 2021). After selecting articles and data obtained, it is observed that gene therapy is able to make changes in specific genes, with the aim of decreasing the level of tumor growth, and can be used in conjunction with bevacizumab, thus increasing the percentage of survival of patients affected by this disease.
Full text article
Generated from XML file
References
1. ABADA.et.al.Genotype-basedselection oftreatmentofpatients withadvancedcolorectalcancer(SETICC):apharmacogenetic-basedrandomizedphaseIItrial.AnnOncol,v.29, nº2,p.439-444,2018.
2. BALDEO, C.; HUGHES, C.L. Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With ColorectalCancer.TechnolCancer Res Treat,v.1, p.18, janeiro, 2019.
3. BIGNUCOLO,A.;DEMATTIA, E.;CECCHIN,E.;RONCATO,R.;TOFFOLI,G. câncer colorretal associado ao papilomavírus humano: uma revisão sistemática commetanálise.RevistaBrasileiradeEpidemiologia, v.19,p. 791-802, 2016.
4. Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC. É razoável adicionar o nível sérico pré-operatório de CEA e CA19-9 ao estadiamento do câncer colorretal? J Surg Res. 2005; 124 : 169–174.
5. COLORECTAL CANCER RISK FACTORS. American cancersociety, 2020. Disponível em: <https://www.cancer.org/cancer/colon-rectal-cancer/causes-risks-prevention/risk-factors.html>. Acesso em: 29 de novembro de 2021.
6. CREMOLINIC.,REM.DEL,ANTONIOTTIC.,LONARDIS.,BERGAMOF.,LOUPAKISF.,BO RELLIB.,MARMORINOF.,CITIV.,CORTESIE.,MORETTOR., RONZONI M., TOMASELLO G. DPYD and UGT1A1 genotyping to predict adverseeventsduringfirst-lineFOLFIRIorFOLFOXIRIplusbevacizumabinmetastaticcolorectalcancer.Oncotarget, v.9,p.7859-7866.
7. DE MATTIA E, BIGNUCOLO A, TOFFOLI G, CECCHIN E. Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy. Curr Med Chem. 2020;27(25):4249-4273. doi: 10.2174/0929867326666190712151417. PMID: 31298142
8. DEURLOO, R.; CHINOT, O.L. Bevacizumab (Avastin®) in cancer treatment: A reviewof15yearsofclinicalexperience andfutureoutlook.CancerTreatVer,v.86.2020.
9. DI SALVATORE, M.; PIETRANTONIO, F.; ORLANDI, A.; DEL RE, M.; BERENATO.R.; ROSSI,E.;CAPORALE,M.;GUARINO,D.;MARTINETTI,A.;BASSO,M.;MENNITTO, R.; SANTONOCITO, C.; MENNITTO, A.; SCHINZARI, G.; BOSSI, I.;CAPOLUONGO,E.POLIMORFISMOS DEDANESIR,DE BRAUDF,BARONE C.IL-8 and eNOS polymorphisms predict bevacizumab- based first line treatmentoutcomes in RAS mutant metastatic colorectal cancer patients. Oncota rget,v.8,nº 10,p.16887-16898,março,2017.
10. GARCIAJ.;HURWITZ,H.I.;SANDLER,A.B.;MILES,D.;COLEMAN,R.L.; HAUSMAN, D.M. What is cancer. Perspectives in Biology and Medicine, v. 62, n° 4,pp. 778-784.2019.
11. HASBULLAH, H.H.; MUSA, M. Gene TherapyTargeting p53 and KRAS for ColorectalCancerTreatment: A Mythorthe Way Forward?.Int J Mol Sci, v. 22, n° 21, p.11941.
12. HOLCH,J.W.;RICARD, I.;STINTZING,S;MODEST,D.P.;HEINEMANN,V.The relevanceofprimarytumourlocation inpatients with metastatic colorectalcancer: A meta- analysis of first- line clinical trials. Eur J Cancer, v. 70, p.87-98,janeiro, 2017.
13. INCA. Instituto Nacional de Câncer. CÂNCER DE INTESTINO. 2021. Disponível em: <https://www.inca.gov.br/tipos-de-cancer/cancer-de-intestino> Acesso em: 21 de Novembro de 2021.
14. INCA. Instituto Nacional do Câncer. O Que é Câncer? 2020. Disponível em: <https://www.inca.gov.br/o-que-e-cancer> Acesso em: 11 de dezembro de 2021.
15. KASI,P.M.;KOEP,T.;SCHNETTLER,E.;SHAHJEHAN,F.;KAMATHAM,V.; BALDEO, C.; HUGHES, C.L. Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With ColorectalCancer.TechnolCancer Res Treat,v.1, p.18, janeiro, 2019.
16. Lech G, Słotwiński R, Słodkowski M, Krasnodębski IW. Marcadores e biomarcadores de tumor de câncer colorretal: avanços terapêuticos recentes. World J Gastroenterol . 2016; 22 (5): 1745-1755. doi: 10.3748 / wjg.v22.i5.1745.
17. MÁRMOL,I;SÁNCHEZ-DE-DIEGO,C;DIESTE, A.P;CERRADA,E;YOLDI,M.J. R.ColorectalCarcinoma:AGeneralOverviewandFuturePerspectivesinColorectalCancer.Int J MolSci, v.19,ed.18, nº1, p.197.2017.
18. Nicolini A, Ferrari P, Duffy MJ, Antonelli A, Rossi G, Metelli MR, Fulceri F, Anselmi L, Conte M, Berti P, et al. Acompanhamento intensivo ajustado ao risco com o painel de marcadores tumorais CEA, TPA, CA19.9 e CA72.4 e ultrassonografia abdominal para diagnosticar recorrências de câncer colorretal operáveis: efeito na sobrevida. Arch Surg. 2010.
19. PACHECO-PÉREZ LA, RUÍZ-GONZÁLEZ KJ, DE-LA-TORRE-GÓMEZ ACG, GUEVARA-VALTIER MC, RODRÍGUEZ-PUENTE LA, GUTIÉRREZ-VALVERDE JM. Environmental factorsandawarenessofcolorectalcancer in peopleat familial risk. RevLatAm Enfermagem. 2019 Oct 14;27:e3195. doi: 10.1590/1518-8345.3082.3195. PMID: 31618388; PMCID: PMC6792335.
20. PAPACHRISTOS,A.;KARATZA,E.;KALOFONOS,H.;SIVOLAPENKO,G. Pharmacogeneti cs inModel-BasedOptimizationofBevacizumabTherapyforMetastaticColorectalCancer. IntJ MolSci,v21,nº 11,p.3753,maio, 2020.
21. PELIZZER,T;PIETA,C.D;POETA,J;TORRIANI,T;RONCADA,C.Prevalênciade Pharmacogeneti cs inModel-BasedOptimizationofBevacizumabTherapyforMetastaticColorectalCancer. IntJ MolSci,v21,nº 11,p.3753,maio, 2020. PharmacogenomicsofTargetedAgentsforPersonalizationofColorectalCancerTreatment.InternationalJournalofMolecularSciences,v.18,n°7,p.1522,2017.
22. RANIERE, G.; CARMELO, L; LAFORGIA, M.; SUMMMA, S.; PORCELLI, M.; MACINA,F.;AMMENDOLA,M.;MOLINARI, P.;LAULETTA,G.;PALO,A.; RUBINI, G.; FERRARI, C.; GADALETA, C. Bevacizumab Plus FOLFOX-4 Combined WithDeepElectro- Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A PilotStudy, v.10,2021.
23. Rivera M, Fichtner I, Wulf-Goldenberg A, et al. Modelos de xenoenxertos derivados de pacientes (PDX) de carcinoma colorretal (CRC) como uma plataforma para quimiossensibilidade e análise de biomarcadores na medicina personalizada. Neoplasia . 2021; 23 (1): 21-35. doi: 10.1016 / j.neo.2020.11.005.
24. Rosen LS, Jacobs IA, Burkes RL. Bevacizumab no câncer colorretal: papel atual no tratamento e o potencial dos biossimilares. Target Oncol . 2017; 12 (5): 599-610. doi: 10.1007 / s11523-017-0518-1.
25. SHENY,WANGX,LUJ,SALFENMOSERM,WIRSIKNM,SCHLEUSSNERN,IMLEA,FREIRE VALLS A, RADHAKRISHNAN P, LIANG J, WANG G, MULEY T, SCHNEIDERM,RUIZDE ALMODOVARC, DIZ-MUÑOZA, SCHMIDTT. Reduction ofLiverMetastasisStiffnessImprovesResponsetoBevacizumabinMetastaticColorectalCancer.Cancer Cell, v.37,nº 6, p.800-817, ed.7. 2020.
26. Weissenberger C, Von Plehn G, Otto F, Barke A, Momm F, Geissler M. Adjuvantradiochemotherapyofstage II e III adenocarcinoma retal: role of CEA andCA 19-9. Anticancer Res. 2005; 25 : 1787–1793.
27. Zhong W, Yu Z, Zhan J, Yu T, Lin Y, Xia ZS, Yuan YH, Chen QK. Associação dos níveis séricos de CEA, CA199, CA125, CYFRA21-1 e CA72-4 e características da doença no câncer colorretal. Pathol Oncol Res. 2015; 21 : 83–95.
2. BALDEO, C.; HUGHES, C.L. Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With ColorectalCancer.TechnolCancer Res Treat,v.1, p.18, janeiro, 2019.
3. BIGNUCOLO,A.;DEMATTIA, E.;CECCHIN,E.;RONCATO,R.;TOFFOLI,G. câncer colorretal associado ao papilomavírus humano: uma revisão sistemática commetanálise.RevistaBrasileiradeEpidemiologia, v.19,p. 791-802, 2016.
4. Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC. É razoável adicionar o nível sérico pré-operatório de CEA e CA19-9 ao estadiamento do câncer colorretal? J Surg Res. 2005; 124 : 169–174.
5. COLORECTAL CANCER RISK FACTORS. American cancersociety, 2020. Disponível em: <https://www.cancer.org/cancer/colon-rectal-cancer/causes-risks-prevention/risk-factors.html>. Acesso em: 29 de novembro de 2021.
6. CREMOLINIC.,REM.DEL,ANTONIOTTIC.,LONARDIS.,BERGAMOF.,LOUPAKISF.,BO RELLIB.,MARMORINOF.,CITIV.,CORTESIE.,MORETTOR., RONZONI M., TOMASELLO G. DPYD and UGT1A1 genotyping to predict adverseeventsduringfirst-lineFOLFIRIorFOLFOXIRIplusbevacizumabinmetastaticcolorectalcancer.Oncotarget, v.9,p.7859-7866.
7. DE MATTIA E, BIGNUCOLO A, TOFFOLI G, CECCHIN E. Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy. Curr Med Chem. 2020;27(25):4249-4273. doi: 10.2174/0929867326666190712151417. PMID: 31298142
8. DEURLOO, R.; CHINOT, O.L. Bevacizumab (Avastin®) in cancer treatment: A reviewof15yearsofclinicalexperience andfutureoutlook.CancerTreatVer,v.86.2020.
9. DI SALVATORE, M.; PIETRANTONIO, F.; ORLANDI, A.; DEL RE, M.; BERENATO.R.; ROSSI,E.;CAPORALE,M.;GUARINO,D.;MARTINETTI,A.;BASSO,M.;MENNITTO, R.; SANTONOCITO, C.; MENNITTO, A.; SCHINZARI, G.; BOSSI, I.;CAPOLUONGO,E.POLIMORFISMOS DEDANESIR,DE BRAUDF,BARONE C.IL-8 and eNOS polymorphisms predict bevacizumab- based first line treatmentoutcomes in RAS mutant metastatic colorectal cancer patients. Oncota rget,v.8,nº 10,p.16887-16898,março,2017.
10. GARCIAJ.;HURWITZ,H.I.;SANDLER,A.B.;MILES,D.;COLEMAN,R.L.; HAUSMAN, D.M. What is cancer. Perspectives in Biology and Medicine, v. 62, n° 4,pp. 778-784.2019.
11. HASBULLAH, H.H.; MUSA, M. Gene TherapyTargeting p53 and KRAS for ColorectalCancerTreatment: A Mythorthe Way Forward?.Int J Mol Sci, v. 22, n° 21, p.11941.
12. HOLCH,J.W.;RICARD, I.;STINTZING,S;MODEST,D.P.;HEINEMANN,V.The relevanceofprimarytumourlocation inpatients with metastatic colorectalcancer: A meta- analysis of first- line clinical trials. Eur J Cancer, v. 70, p.87-98,janeiro, 2017.
13. INCA. Instituto Nacional de Câncer. CÂNCER DE INTESTINO. 2021. Disponível em: <https://www.inca.gov.br/tipos-de-cancer/cancer-de-intestino> Acesso em: 21 de Novembro de 2021.
14. INCA. Instituto Nacional do Câncer. O Que é Câncer? 2020. Disponível em: <https://www.inca.gov.br/o-que-e-cancer> Acesso em: 11 de dezembro de 2021.
15. KASI,P.M.;KOEP,T.;SCHNETTLER,E.;SHAHJEHAN,F.;KAMATHAM,V.; BALDEO, C.; HUGHES, C.L. Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With ColorectalCancer.TechnolCancer Res Treat,v.1, p.18, janeiro, 2019.
16. Lech G, Słotwiński R, Słodkowski M, Krasnodębski IW. Marcadores e biomarcadores de tumor de câncer colorretal: avanços terapêuticos recentes. World J Gastroenterol . 2016; 22 (5): 1745-1755. doi: 10.3748 / wjg.v22.i5.1745.
17. MÁRMOL,I;SÁNCHEZ-DE-DIEGO,C;DIESTE, A.P;CERRADA,E;YOLDI,M.J. R.ColorectalCarcinoma:AGeneralOverviewandFuturePerspectivesinColorectalCancer.Int J MolSci, v.19,ed.18, nº1, p.197.2017.
18. Nicolini A, Ferrari P, Duffy MJ, Antonelli A, Rossi G, Metelli MR, Fulceri F, Anselmi L, Conte M, Berti P, et al. Acompanhamento intensivo ajustado ao risco com o painel de marcadores tumorais CEA, TPA, CA19.9 e CA72.4 e ultrassonografia abdominal para diagnosticar recorrências de câncer colorretal operáveis: efeito na sobrevida. Arch Surg. 2010.
19. PACHECO-PÉREZ LA, RUÍZ-GONZÁLEZ KJ, DE-LA-TORRE-GÓMEZ ACG, GUEVARA-VALTIER MC, RODRÍGUEZ-PUENTE LA, GUTIÉRREZ-VALVERDE JM. Environmental factorsandawarenessofcolorectalcancer in peopleat familial risk. RevLatAm Enfermagem. 2019 Oct 14;27:e3195. doi: 10.1590/1518-8345.3082.3195. PMID: 31618388; PMCID: PMC6792335.
20. PAPACHRISTOS,A.;KARATZA,E.;KALOFONOS,H.;SIVOLAPENKO,G. Pharmacogeneti cs inModel-BasedOptimizationofBevacizumabTherapyforMetastaticColorectalCancer. IntJ MolSci,v21,nº 11,p.3753,maio, 2020.
21. PELIZZER,T;PIETA,C.D;POETA,J;TORRIANI,T;RONCADA,C.Prevalênciade Pharmacogeneti cs inModel-BasedOptimizationofBevacizumabTherapyforMetastaticColorectalCancer. IntJ MolSci,v21,nº 11,p.3753,maio, 2020. PharmacogenomicsofTargetedAgentsforPersonalizationofColorectalCancerTreatment.InternationalJournalofMolecularSciences,v.18,n°7,p.1522,2017.
22. RANIERE, G.; CARMELO, L; LAFORGIA, M.; SUMMMA, S.; PORCELLI, M.; MACINA,F.;AMMENDOLA,M.;MOLINARI, P.;LAULETTA,G.;PALO,A.; RUBINI, G.; FERRARI, C.; GADALETA, C. Bevacizumab Plus FOLFOX-4 Combined WithDeepElectro- Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A PilotStudy, v.10,2021.
23. Rivera M, Fichtner I, Wulf-Goldenberg A, et al. Modelos de xenoenxertos derivados de pacientes (PDX) de carcinoma colorretal (CRC) como uma plataforma para quimiossensibilidade e análise de biomarcadores na medicina personalizada. Neoplasia . 2021; 23 (1): 21-35. doi: 10.1016 / j.neo.2020.11.005.
24. Rosen LS, Jacobs IA, Burkes RL. Bevacizumab no câncer colorretal: papel atual no tratamento e o potencial dos biossimilares. Target Oncol . 2017; 12 (5): 599-610. doi: 10.1007 / s11523-017-0518-1.
25. SHENY,WANGX,LUJ,SALFENMOSERM,WIRSIKNM,SCHLEUSSNERN,IMLEA,FREIRE VALLS A, RADHAKRISHNAN P, LIANG J, WANG G, MULEY T, SCHNEIDERM,RUIZDE ALMODOVARC, DIZ-MUÑOZA, SCHMIDTT. Reduction ofLiverMetastasisStiffnessImprovesResponsetoBevacizumabinMetastaticColorectalCancer.Cancer Cell, v.37,nº 6, p.800-817, ed.7. 2020.
26. Weissenberger C, Von Plehn G, Otto F, Barke A, Momm F, Geissler M. Adjuvantradiochemotherapyofstage II e III adenocarcinoma retal: role of CEA andCA 19-9. Anticancer Res. 2005; 25 : 1787–1793.
27. Zhong W, Yu Z, Zhan J, Yu T, Lin Y, Xia ZS, Yuan YH, Chen QK. Associação dos níveis séricos de CEA, CA199, CA125, CYFRA21-1 e CA72-4 e características da doença no câncer colorretal. Pathol Oncol Res. 2015; 21 : 83–95.
Authors
Lucas Santos de Oliveira, T. S. M. A. B. S. dos S. ., Marisa Salvi, & Marcus Vinícius Cardoso. (2022). THE USE OF GENE THERAPY THROUGH BEVACIZUMAB IN THE TREATMENT OF COLORECTAL CANCER AN INTEGRATIVE REVIEW. Journal of Medical Care Research and Review, 4(12). Retrieved from http://mcrr.info/index.php/mcrr/article/view/204
Copyright and license info is not available